Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events

Evaluation of the bioactivity of influenza vaccine strains in vitro suggests that the introduction of new strains in the 2010 Southern Hemisphere Trivalent Influenza Vaccine is associated with adverse events

Highlights • CSL TIVs, as a class, induce greater cytokines/gene signatures compared to other licensed TIVs. • Subset of paediatric donors more responsive to components within the CSL 2010 SH TIV than previous season's CSL TIVs. • CSL standard method of manufacture preserved viral components of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2014-06, Vol.32 (30), p.3861-3868
Hauptverfasser: Rockman, Steve, Dyson, Allison, Koernig, Sandra, Becher, Dorit, Ng, Milica, Morelli, Adriana Baz, Barnden, Megan, Tang, Mimi L.K, Pearse, Martin, Maraskovsky, Eugene
Format: Artikel
Sprache:eng
Schlagworte:
Adverse events
Allergy and Immunology
Applied microbiology
Australia - epidemiology
Biological and medical sciences
Chemokines
Chemokines - immunology
Child
Child, Preschool
Cytokines
Cytokines - immunology
Febrile reactions
Fundamental and applied biological sciences. Psychology
HEK293 Cells
Humans
Immune response
Infant
Influenza A Virus, H1N1 Subtype
Influenza A Virus, H3N2 Subtype
Influenza B virus
Influenza Vaccines - adverse effects
Influenza Vaccines - immunology
Influenza, Human - prevention & control
Microbiology
NF-kappa B - metabolism
NF-kappaB
Paediatric
Product Surveillance, Postmarketing
Seasonal trivalent influenza vaccine
Seizures, Febrile - chemically induced
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights • CSL TIVs, as a class, induce greater cytokines/gene signatures compared to other licensed TIVs. • Subset of paediatric donors more responsive to components within the CSL 2010 SH TIV than previous season's CSL TIVs. • CSL standard method of manufacture preserved viral components of the 2010 SH strains. • Combination of B/Brisbane/60/2008 with A/California/07/2009 in CSL 2010 SH TIV resulted in heightened cytokines/immune activation. • Heightened immune responses in a proportion of children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2014.03.032